Clinical Trial Update: Talazoparib For Neoadjuvant Treatment Of Germline BRCA1/2 Mutation Patients With Early Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of talazoparib as neoadjuvant therapy in germline BRCA1/2 mutation-bearing, HER2-negative early breast cancer; the study is terminated with posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Talazoparib (talazoparib)

Snippet

Sponsor: Pfizer | Conditions: Early Breast Cancer | Phase 2 | Status: TERMINATED | Results posted: 2021-11-09